Deaths From PSA-Detected Prostate Cancer Low at 15 Years, No Matter the Treatment
For prostate cancers detected by screening, cancer-specific mortality was low at 15-year follow-up regardless of whether patients underwent active monitoring, prostatectomy, or radiotherapy, results from the phase III randomized ProtecT study showed. Among over 1,600 men from the U.K. with prostate cancers detected by a prostate-specific antigen (PSA) test, death from their malignancy occurred in […]